• Not yet recruiting

NCT05461209: Phase 3: Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)

(MonumenTAL-5)

NCT05461209: Phase 3: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)

Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)

NCT05461209: Phase 3: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)


The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).


Sponsor

Janssen Research & Development, LLC

 

ClinicalTrials.gov Identifier: NCT05461209

Official Title: A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an Anti-CD38 Antibody

First Posted : July 18, 2022

Click here to see details on ClinicalTrials.gov

 

Talquetamab

Talquetamab (Code C171840)

Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564

GPRC5D x CD3 Bispecific Antibody JNJ-64407564

GPRC5D x CD3 DuoBody Antibody JNJ-64407564

GPRC5D/CD3 DuoBody Antibody JNJ-64407564

Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564

JNJ 64407564

JNJ-64407564

JNJ64407564

Talquetamab

TALQUETAMAB

 

Drug: Talquetamab

Drug: Belantamab Mafodotin

 

Locations

United States, Arkansas

United States, California

United States, District of Columbia

United States, Louisiana

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Missouri

United States, New Jersey

United States, North Carolina

United States, Ohio

United States, Pennsylvania

United States, Texas

United States, Utah

United States, Wisconsin

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Canada

Europe

Czechia

Germany

Israel

Italy

Poland

Portugal

Spain

United Kingdom

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

Click here for details


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

Click here for details


NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

Click here for details


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

Click here for details


NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Click here for details


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Click here for details

 

TALQUETAMAB STUDIES:


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

Click here for details

Posts Archive